Journal of Affective Disorders
June 8, 2026
Dian‐jeng Li, Tien-Wei Hsu, Te-Chang Changchien et al.
Little is known about esketamine's effectiveness for patients with major depressive disorder (MDD) comorbid substance use disorders (SUD). We conducted a retrospective cohort study using the TriNetX US Collaborative Network, including adults aged ≥18 years with MDD. Three propensity-score-matched (1:1) cohorts were defined based on treatment: esketamine, antidepressant-only, and repetitive...
Journal of Affective Disorders
January 15, 2025
Jia-Ru Li, Kuo-Tung Chiang, Yu-Chen Kao et al.
1 citation
Different study designs of psychedelic trials may impact the blinding and expectance, leading to biased treatment effects. This study aimed to examine the association between antidepressant efficacy and study designs in psychedelic trials. Six databases were systematically searched. Eligible trials were required to investigate the efficacy of psychedelics (psilocybin, lysergic acid diethylamide...
BMJ
August 21, 2024
Trevor Thompson, Ping-Tao Tseng, Chih-Wei Hsu et al.
24 citations
Abstract Objective To evaluate the comparative effectiveness and acceptability of oral monotherapy using psychedelics and escitalopram in patients with depressive symptoms, considering the potential for overestimated effectiveness due to unsuccessful blinding. Design Systematic review and Bayesian network meta-analysis. Data sources Medline, Cochrane Central Register of Controlled Trials,...
Frontiers in Psychiatry
August 13, 2024
Mu-Hong Chen, Shu-Li Cheng, Yu-Chen Kao et al.
8 citations
Objective Psilocybin-assisted therapy has shown promising efficacy on clinical depressive symptoms. However, diverse psychological support or psychotherapy was performed with psilocybin treatment. This study aimed to explore the association of psychological protocols with the efficacy of psilocybin-assisted therapy for depressive symptoms. Method Five major databases were systemic searched for...
Journal of Clinical Medicine
February 11, 2022
Chia‐ling Yu, Chih-Sung Liang, Fu-Chi Yang et al.
37 citations
We examined the cardiovascular safety, acceptability, and trajectory of the antidepressant effects of psilocybin after single- or two-dose administration. Four major electronic databases were systematically searched. Data were pooled using a multivariate random-effects meta-analysis. Primary outcomes were changes in depressive symptoms. Secondary outcomes were cardiovascular safety and...
Psychiatry Investigation
October 10, 2021
Chia‐ling Yu, Fu-Chi Yang, Szu‐nian Yang et al.
57 citations
Objective To systematically examine the effectiveness and tolerability of psilocybin for treating end-of-life anxiety symptoms.Methods The Medline, Embase, CENTRAL, and PsycINFO databases were searched up to November 25, 2020. We enrolled clinical trials investigating psilocybin for treating end-of-life anxiety symptoms. Meta-analysis was conducted using random-effects model.Results Overall,...